Company Accounts and Tax Online 14069739 Board of Directors 1.5.24 31.5.25 31.5.25 false iso4217:GBP xbrli:pure 14069739 2023-05-01 2024-04-30 14069739 2025-05-31 14069739 2024-05-01 2025-05-31 14069739 2024-04-30 14069739 countries:EnglandWales 2024-05-01 2025-05-31 14069739 curr:PoundSterling 2024-05-01 2025-05-31 14069739 uk-bus:PrivateLimitedCompanyLtd 2024-05-01 2025-05-31 14069739 uk-bus:FRS102 2024-05-01 2025-05-31 14069739 uk-bus:AuditExempt-NoAccountantsReport 2024-05-01 2025-05-31 14069739 uk-bus:AbridgedAccounts 2024-05-01 2025-05-31 14069739 uk-bus:RegisteredOffice 2024-05-01 2025-05-31 14069739 uk-bus:Director1 2024-05-01 2025-05-31 14069739 uk-bus:Director1 2024-05-01 14069739 uk-bus:Director1 2025-05-31 14069739 core:AfterOneYear 2025-05-31 14069739 core:AfterOneYear 2024-04-30 14069739 core:WithinOneYear 2025-05-31 14069739 core:WithinOneYear 2024-04-30 14069739 core:WithinOneYear 2024-05-01 2025-05-31 14069739 core:AfterOneYear 2025-05-31 14069739 core:AfterOneYear 2024-04-30 14069739 core:AfterOneYear 2024-05-01 2025-05-31 14069739 core:ShareCapital 2025-05-31 14069739 core:ShareCapital 2024-04-30 14069739 core:RevaluationReserve 2025-05-31 14069739 core:RevaluationReserve 2024-04-30 14069739 core:RetainedEarningsAccumulatedLosses 2025-05-31 14069739 core:RetainedEarningsAccumulatedLosses 2024-04-30 14069739 1 2024-05-01 2025-05-31

# TEK PHARM. LTD

## Company Registration Number:
14069739 (England and Wales)

## Unaudited abridged accounts for the year ended 31 May 2025

## Period of accounts

## Start date: 01 May 2024

## End date: 31 May 2025

# TEK PHARM. LTD

## Contents of the Financial Statements

for the Period Ended 31 May 2025

Company Information - 3 |
Report of the Directors - 4 |
Balance sheet - 5 |
Additional notes - 7 |
Balance sheet notes - 10 |

# TEK PHARM. LTD

## Company Information

for the Period Ended 31 May 2025

Director: |  | Teklit GEBREKIRSTOS
Registered office: |  | 130a Canterbury Road Morden England SM4 6QP
Company Registration Number: |  | 14069739 (England and Wales)

# TEK PHARM. LTD

## Directors' Report Period Ended 31 May 2025

The directors present their report with the financial statements of the company for the period ended 31 May 2025

Principal Activities

The company's principal activity continues to be that of providing human health activities services.

Directors

The directors shown below have held office during the whole of the period from 01 May 2024 to 31 May 2025
Teklit GEBREKIRSTOS

This report was approved by the board of directors on 22 January 2026
And Signed On Behalf Of The Board By:

Name: Teklit GEBREKIRSTOS
Status: Director

# TEK PHARM. LTD

## Balance sheet

As at 31 May 2025

| Notes | 13 months to 31 May 2025 £ | 2024 £
--- | --- | --- | ---
Fixed assets
Tangible assets: | 4 | 17,733 | 21,625
Total fixed assets: |  | 17,733 | 21,625
Current assets
Debtors: |  | 72,575 |
Cash at bank and in hand: |  | 1,793 | 45,028
Total current assets: |  | 74,368 | 45,028
Creditors: amounts falling due within one year: |  | ( 6,300 ) | ( 4,746 )
Net current assets (liabilities): |  | 68,068 | 40,282
Total assets less current liabilities: |  | 85,801 | 61,907
Creditors: amounts falling due after more than one year: |  | ( 26,843 ) | ( 26,843 )
Total net assets (liabilities): |  | 58,958 | 35,064

The notes form part of these financial statements

# TEK PHARM. LTD

## Balance sheet continued

As at 31 May 2025

| Notes | 13 months to 31 May 2025 £ | 2024 £
--- | --- | --- | ---
Capital and reserves
Called up share capital: |  | 1 | 1
Profit and loss account: |  | 58,957 | 35,063
Shareholders funds: |  | 58,958 | 35,064

For the year ending 31 May 2025 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

The members have agreed to the preparation of abridged accounts for this accounting period in accordance with Section 444(2A).

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

This report was approved by the board of directors on 22 January 2026
And Signed On Behalf Of The Board By:

Name: Teklit GEBREKIRSTOS
Status: Director

The notes form part of these financial statements

# TEK PHARM. LTD

## Notes to the Financial Statements

for the Period Ended 31 May 2025

- ## 1. Accounting policies

  Basis of measurement and preparation

  These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

  Turnover policy

  Turnover shown in the profit and loss account represents revenue earned during the period, exclusive of VAT.

# TEK PHARM. LTD

## Notes to the Financial Statements

for the Period Ended 31 May 2025

- ## 2. Employees

  | 13 months to 31 May 2025 | 2024
  --- | --- | ---
  Average number of employees during the period | 1 | 1

# TEK PHARM. LTD

## Notes to the Financial Statements

for the Period Ended 31 May 2025

- ## 3. Off balance sheet disclosure

  No

# TEK PHARM. LTD

## Notes to the Financial Statements

for the Period Ended 31 May 2025

## 4. Tangible Assets

| Total
--- | ---
Cost | £
At 01 May 2024 | 25,000
Additions | -
Disposals | -
Revaluations | -
Transfers | -
At 31 May 2025 | 25,000
Depreciation |
At 01 May 2024 | 3,375
Charge for year | 3,892
On disposals | -
Other adjustments | -
At 31 May 2025 | 7,267
Net book value |
At 31 May 2025 | 17,733
At 30 April 2024 | 21,625